Get access

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population

Authors


  • Author contribution: K. V. P. contributed to the collection and analysis of the data, and the writing; T. M. contributed to the organization of the study, collection and analysis of the data, and the writing; the RODOS study group contributed to the collection of the data.

Professor Dr Tony Mets, Head of Department, Gerontology and Geriatrics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B-1090 Brussels, Belgium. Email: tmets@vub.ac.be

Abstract

Aim:  To record in real life the appreciation of elderly patients, their caregivers and physicians of a once daily formulation of prolonged release of galantamine in the treatment of mild to moderate Alzheimer's disease.

Methods:  A prospective, multicenter, observational study was conducted in 128 elderly patients, treated for 6 months with galantamine, donepezil or rivastigmine.

Results:  Of the patients treated with galantamine, 82 of the 97 (84.5%) were continuing their treatment after 6 months. These patients reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P < 0.001). The incidence of serious side-effects possibly related to galantamine was 9.3%, which was not different from that in patients treated with other cholinesterase inhibitors.

Conclusion:  In a real life setting, galantamine once daily is safe and is favorably appreciated by patients, their caregivers and physicians. Geriatr Gerontol Int 2011; 11: 256–261.

Ancillary